BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Clinical trial NCT03749187 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03749187
Sponsor: University of California, San Francisco
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Glioblastoma IDH1 Gene Mutation IDH2 Gene Mutation Low Grade Glioma Malignant Glioma Recurrent Glioblastoma Recurrent WHO Grade II Glioma Recurrent WHO Grade III Glioma WHO Grade II Glioma WHO Grade III Glioma

Start date: 2019-04-03
Primary completion: 2026-06-30
Enrollment: 78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.